<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941547</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI055</org_study_id>
    <nct_id>NCT04941547</nct_id>
  </id_info>
  <brief_title>Association Between Cancer and Anti-synthetase Syndrome</brief_title>
  <official_title>Association Between Cancer and Anti-synthetase Syndrome : a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHU Dijon Bourgogne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpitaux Privés de Metz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among Idiopathic inflammatory myopathies, antisynthetase syndrome is meant to be rarely&#xD;
      associated with cancer. However, clinical evidences of the association of those diseases led&#xD;
      to the hypothesis that previous studies might have underestimated the prevalence of cancer in&#xD;
      patients with antisynthetase syndrome. The aim of this study was to assess the prevalence of&#xD;
      cancer in patients with antisynthetases syndrome in Grand Est and Bourgogne Franche-Comté&#xD;
      regions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic inflammatory myopathies area heterogeneous group of disease involving mainly&#xD;
      muscles, which paraneoplastic feature has been well characterized, specifically in some&#xD;
      subgroups such as dermatomyositis. In contrast, antisynthetase syndrome is thought to be&#xD;
      rarely associated with cancer. However, clinical observations of the association of those&#xD;
      diseases led us to the hypothesis that previous studies might have underestimated the&#xD;
      prevalence of cancer in patients with antisynthetase syndrome. The aim of this study was to&#xD;
      assess the prevalence of cancer in patients with antisynthetases syndrome in Grand Est and&#xD;
      Bourgogne Franche-Comté regions, describing the type of cancer observed as well as clinical&#xD;
      features of patients and diagnostic work-up leading to the diagnosis of cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cancer prevalence</measure>
    <time_frame>baseline</time_frame>
    <description>prevalence of cancer among patients with antisynthetase syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>description of cancer type in patients with antisynthetase syndrome</measure>
    <time_frame>baseline</time_frame>
    <description>description of the type and stage of cancer in patients with antisynthetase syndrome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>factors associated with cancer</measure>
    <time_frame>baseline</time_frame>
    <description>comparison of clinical and paraclinical features associated with cancer in patients with antisynthetase syndrome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Antisynthetase Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with antisynthetase syndrome, defined by the positivity of antisynthetase&#xD;
        antibodies and the presence of at least one clinical involvment, are included, either with&#xD;
        or without cancer, to allow comparison of patients according to the presence of cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients&#xD;
&#xD;
          -  positive antisynthetase antibodies (JO-1,PL12, PL17, EJ, OJ, KS, RS, YRS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18&#xD;
&#xD;
          -  opposition to data collection&#xD;
&#xD;
          -  no positive antisynthetase antibodies&#xD;
&#xD;
          -  absence of clinical involvment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Moulinet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Moulinet, MD</last_name>
    <phone>0686252853</phone>
    <email>t.moulinet@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Moulinet</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <state>Lorraine</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Moulinet</last_name>
      <phone>0686252853</phone>
      <email>t.moulinet@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>idiopathic inflammatory myopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

